Skip to content

A clinical study of hydromorphone PCA in the treatment of postherpetic neuralgia

A clinical study of hydromorphone PCA in the treatment of postherpetic neuralgia

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084212
Enrollment
Unknown
Registered
2024-05-13
Start date
2024-05-20
Completion date
Unknown
Last updated
2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postherpetic neuralgia

Interventions

Test group:Continuous PCA analgesia with hydromorphone combined with pulsed radiofrequency
Control group:Pulsed radiofrequency

Sponsors

Shengli Oilfield Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age 50-80 years, gender unlimited, diagnosed with postherpetic neuralgia in thoracic nerve distribution, course of disease 1 to 3 months, NRS score =6, no serious heart, lung, liver, kidney and other systemic diseases, and willingness to comply with designated treatment and follow-up.

Exclusion criteria

Exclusion criteria: Significant pain, coagulopathy, psychiatric illness, substance abuse, previous hydromorphone allergy, lack of cooperation, and severe systemic, metabolic, or neurologic disease from causes other than PHN.

Design outcomes

Primary

MeasureTime frame
Response rate;

Secondary

MeasureTime frame
Number of self-control analgesia sessions;Dosage of analgesic drugs used;Degree of pain relief;Sleep Quality Index;

Countries

China

Contacts

Public ContactWeipeng Ge

Shengli Oilfield Central Hospital

slytzxyyttk@163.com+86 189 5403 2017

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026